Clinical Research Focus. 53rd Edition

NIH Researchers Identify First Human Antibodies Capable of Neutralizing Measles Virus 

NIH-funded scientists have identified and mapped the first comprehensive suite of human antibodies targeting the measles virus, potentially laying the foundation for future antibody-based measles treatments. The discovery comes amid rising global measles outbreaks and could become especially important for vulnerable patients who cannot safely receive vaccination, including immunocompromised individuals, pregnant women, and infants. 

Learn more

FDA, AI, and the Future of Clinical Trials 

AI in clinical trials is entering a new phase. The FDA is no longer focusing only on operational efficiency and automation, but increasingly on governance, oversight, transparency, and trust. As regulators begin integrating AI into the broader infrastructure of clinical development, the future of clinical trials may depend not just on using AI, but on how reliably and responsibly it can operate within regulated environments. 

Learn more 

EMA Recommends First Oral GLP-1 Therapy for Weight Management 

The EMA has recommended approval of the first oral GLP-1 treatment for weight management in Europe, with Wegovy tablets offering an alternative to weekly injections. The decision could mark an important shift in the obesity treatment landscape by expanding access and convenience for patients, while further accelerating the global growth of the GLP-1 market. 

Learn more 

World Clinical Trials Day: Clinical Research Is Not Where It Used to Be 

World Clinical Trials Day is no longer only about innovation and breakthroughs. As clinical trials become more complex, the industry’s biggest challenge is shifting toward execution, operational pressure, patient recruitment, AI integration, and the ability to deliver studies efficiently at scale. 

Learn more 

FDA Approves First Ever Treatment for Chronic Hepatitis Delta 

The FDA has approved Hepcludex (bulevirtide), the first-ever FDA-approved therapy for chronic hepatitis delta virus (HDV) infection — one of the most severe forms of viral hepatitis linked to rapid liver damage, cancer, and liver failure. The approval marks a major milestone for patients who previously had no approved treatment options and highlights the growing focus on accelerating therapies for rare and high unmet-need diseases. 

Learn more

The US–UK Pharma Deal Is Bigger Than It Looks 

The recent US–UK pharmaceutical agreement may signal something much bigger than a trade deal. As pricing pressure grows and China accelerates biotech investment, governments are increasingly treating pharma not just as healthcare, but as a strategic industry tied to innovation, competitiveness, and geopolitical influence — a shift that could reshape the future rules of global biopharma. 

Learn more 

CRO in Poland: Why Poland Should Be a Core Country for Oncology Clinical Trials in Europe   

Poland is no longer just a cost-efficient market for oncology trials. With strong patient access, experienced investigators, growing investment in research infrastructure, and full EU regulatory alignment, the country is increasingly becoming a strategically important hub for oncology clinical trial execution in Europe. 

Learn more 

Lilly’s Next-Generation Obesity Drug Delivers Nearly 30% Weight Loss in Phase 3 Trial 

Eli Lilly has reported Phase 3 results showing that its experimental triple agonist obesity drug retatrutide achieved up to 28.3% average weight loss, with some patients exceeding 30% — results approaching levels historically associated with bariatric surgery. The data may mark one of the most significant advances yet in the rapidly evolving obesity drug race and further intensify competition within the multi-billion-dollar GLP-1 market. 

Learn more

New Parkinson’s Trial Data Signals Progress in Neurodegenerative Drug Development 

Biogen and Denali Therapeutics reported new Phase IIb data in Parkinson’s disease, highlighting continued momentum in one of the most challenging areas of modern drug development. As neurodegenerative diseases remain a major unmet medical need, advances in brain-targeted therapies and blood-brain barrier technologies are increasingly attracting industry and investor attention. 

Learn more